-
公开(公告)号:WO9221313A3
公开(公告)日:1993-01-07
申请号:PCT/US9204391
申请日:1992-05-26
Applicant: VERTEX PHARMA
Inventor: DUFFY JOHN P
IPC: A61K31/18 , A61K31/40 , A61K31/4427 , A61K31/4433 , A61K31/445 , A61P37/06 , C07C311/02 , C07D207/48 , C07D211/60 , C07D211/96 , C07D401/12 , C07D409/12 , A61K31/215 , A61K31/395 , C07C311/00 , C07D409/06
CPC classification number: C07D211/96 , C07D207/48
Abstract: This invention relates to anovel class of immuno-suppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
-
2.
公开(公告)号:WO2005056547A2
公开(公告)日:2005-06-23
申请号:PCT/US2004040777
申请日:2004-12-03
Applicant: VERTEX PHARMA , BEMIS GUY W , DUFFY JOHN P
Inventor: BEMIS GUY W , DUFFY JOHN P
IPC: A61K31/498 , C07D241/26 , C07D241/44 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07D487/02 , A61P35/00
CPC classification number: C07D241/26 , C07D241/44 , C07D401/12 , C07D403/12 , C07D417/12
Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
Abstract translation: 本发明涉及可用作蛋白激酶抑制剂的化合物。 本发明还提供包含所述化合物的药学上可接受的组合物和使用该组合物治疗各种疾病,病症或病症的方法。
-
公开(公告)号:WO2012083122A8
公开(公告)日:2013-12-05
申请号:PCT/US2011065389
申请日:2011-12-16
Applicant: VERTEX PHARMA , CHARIFSON PAUL S , CLARK MICHAEL P , BANDARAGE UPUL K , DENG HONGBO , DAVIES IOANA , DUFFY JOHN P , FARMER LUC J , GAO HUAI , GU WENXIN , KENNEDY JOSEPH M , LEDEBOER MARK W , LEDFORD BRIAN , MALTAIS FRANCOIS , PEROLA EMANUELE , WANNAMAKER MARION W , WANG TIANSHENG , SALITURO FRANCESCO G
Inventor: CHARIFSON PAUL S , CLARK MICHAEL P , BANDARAGE UPUL K , DENG HONGBO , DAVIES IOANA , DUFFY JOHN P , FARMER LUC J , GAO HUAI , GU WENXIN , KENNEDY JOSEPH M , LEDEBOER MARK W , LEDFORD BRIAN , MALTAIS FRANCOIS , PEROLA EMANUELE , WANNAMAKER MARION W , WANG TIANSHENG , SALITURO FRANCESCO G
IPC: C07D471/04 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/53
CPC classification number: C07D471/04
Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
Abstract translation: 抑制生物样品或患者中流感病毒的复制,减少生物样品或患者中流感病毒的量以及治疗患者中的流感的方法包括向所述生物样品或患者施用有效量的 由结构式(I)表示的化合物或其药学上可接受的盐,其中结构式(I)的值如本文所述。 结构式(I)表示的化合物或其药学上可接受的盐,其中结构式(I)的值如本文所述。 药物组合物包含有效量的这样的化合物或其药学上可接受的盐和药学上可接受的载体,助剂或媒介物。
-
公开(公告)号:WO2013163190A8
公开(公告)日:2014-11-27
申请号:PCT/US2013037811
申请日:2013-04-23
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL S , COTTRELL KEVIN MICHAEL , DENG HONGBO , DUFFY JOHN P , GAO HUAI , GIROUX SIMON , GREEN JEREMY , JACKSON KATRINA LEE , MAXWELL JOHN PATRICK , MORRIS MARK A , PIERCE ALBERT CHARLES , WAAL NATHAN D , KENNEDY JOSEPH M , LAUFFER DAVID J , LEDEBOER MARK WILLEM , LI PAN , XU JINWANG
IPC: C07D401/14 , C07D239/42 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D491/048
CPC classification number: A61K31/506 , A61K9/20 , A61K9/48 , A61K31/5377 , A61K41/0038 , A61K47/481 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/10 , C07D417/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D495/04 , C07D521/00
Abstract: The present invention relates to compounds of following formula (I) useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders, such as cancer.
Abstract translation: 本发明涉及可用作DNA-PK抑制剂的下式(I)化合物。 本发明还提供包含所述化合物的药学上可接受的组合物和使用该组合物治疗各种疾病,病症或病症例如癌症的方法。
-
公开(公告)号:PL3459942T3
公开(公告)日:2021-10-11
申请号:PL18186230
申请日:2013-04-23
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL S , COTTRELL KEVIN MICHAEL , DENG HONGBO , DUFFY JOHN P , GAO HUAI , GIROUX SIMON , GREEN JEREMY , JACKSON KATRINA LEE , MAXWELL JOHN PATRICK , MORRIS MARK A , PIERCE ALBERT CHARLES , WAAL NATHAN D , KENNEDY JOSEPH M , LAUFFER DAVID J , LEDEBOER MARK WILLEM , LI PAN , XU JINWANG
IPC: C07D401/14 , A61K31/506 , A61K41/00 , A61P35/00 , C07D239/42 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D495/04
-
公开(公告)号:CA2871471C
公开(公告)日:2021-06-01
申请号:CA2871471
申请日:2013-04-23
Applicant: VERTEX PHARMA
Inventor: GAO HUAI , CHARIFSON PAUL S , COTTRELL KEVIN MICHAEL , DENG HONGBO , DUFFY JOHN P , GIROUX SIMON , GREEN JEREMY , JACKSON KATRINA LEE , MAXWELL JOHN PATRICK , MORRIS MARK A , PIERCE ALBERT CHARLES , WAAL NATHAN D , LAUFFER DAVID J , KENNEDY JOSEPH M , LEDEBOER MARK WILLEM , LI PAN , XU JINWANG
IPC: C07D401/14 , C07D239/42 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D491/048
Abstract: The present invention relates to compounds of following formula (I) useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders, such as cancer.
-
公开(公告)号:DK3459942T3
公开(公告)日:2021-03-08
申请号:DK18186230
申请日:2013-04-23
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL S , COTTRELL KEVIN MICHAEL , DENG HONGBO , DUFFY JOHN P , GAO HUAI , GIROUX SIMON , GREEN JEREMY , JACKSON KATRINA LEE , MAXWELL JOHN PATRICK , MORRIS MARK A , PIERCE ALBERT CHARLES , WAAL NATHAN D , KENNEDY JOSEPH M , LAUFFER DAVID J , LEDEBOER MARK WILLEM , LI PAN , XU JINWANG
IPC: C07D401/14 , A61K31/506 , A61K41/00 , A61P35/00 , C07D239/42 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D491/048 , C07D491/056 , C07D495/04
-
公开(公告)号:UA122808C2
公开(公告)日:2021-01-06
申请号:UAA201807026
申请日:2012-08-01
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL S , CLARK MICHAEL P , BANDARAGE UPUL K , BETHIEL RANDY S , BOYD MICHAEL J , DAVIES IOANA , DENG HONGBO , DUFFY JOHN P , FARMER LUC J , GAO HUAI , GU WENXIN , KENNEDY JOSEPH M , LEDFORD BRIAN , LEDEBOER MARK W , MALTAIS FRANCOIS , PEROLA EMANUELE , WANG TIANSHENG
Abstract: Способиінгібуванняреплікаціївірусугрипув біологічномузразкуабов пацієнта, зменшеннякількостівірусугрипув біологічномузразкуабов пацієнтаі лікуваннягрипув пацієнтавключаютьвведенняу вказанийбіологічнийзразокабопацієнтуефективноїкількостісполуки, щовідповідаєструктурнійформулі (I): абоїїфармацевтичноприйнятноїсолі, дезмінніструктурноїформули (I) єтакими, якописанов даномуописі. Сполукавідповідаєструктурнійформулі (I) абоструктурнійформуліїїфармацевтичноприйнятноїсолі, дезмінніструктурноїформули (I) єтакими, якописанов даномуописі. Фармацевтичнакомпозиціяміститьефективнукількістьтакоїсполукиабоїїфармацевтичноприйнятноїсоліі фармацевтичноприйнятнийносій, ад'ювантабонаповнювач.
-
公开(公告)号:CA2844054C
公开(公告)日:2020-09-01
申请号:CA2844054
申请日:2012-08-01
Applicant: VERTEX PHARMA
Inventor: CHARIFSON PAUL S , CLARK MICHAEL P , BANDARAGE UPUL K , BETHIEL RANDY S , BOYD MICHAEL J , DAVIES IOANA , DENG HONGBO , DUFFY JOHN P , FARMER LUC J , GAO HUAI , GU WENXIN , KENNEDY JOSEPH M , LEDFORD BRIAN , LEDEBOER MARK W , MALTAIS FRANCOIS , PEROLA EMANUELE , WANG TIANSHENG
IPC: C07D471/04 , A61K31/444 , A61K31/506 , A61P31/16
Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
-
公开(公告)号:AR113753A2
公开(公告)日:2020-06-10
申请号:ARP180102912
申请日:2018-10-09
Applicant: VERTEX PHARMA
Inventor: WANNAMAKER M WOODS , WANG TIANSHENG , PEROLA EMANUELE , MALTAIS FRANCOIS , LEDFORD BRIAN , LEDEBOER MARK W , KENNEDY JOSEPH M , JACOBS DYLAN H , GU WENXIN , GAO HUAI , FARMER LUC J , DUFFY JOHN P , DRUTU IOANA , DENG HONGBO , COURT JOHN J , BETHIEL RANDY S , CLARK MICHAEL P , CHARIFSON PAUL
IPC: A61K31/437 , A61P31/16 , C07D471/04
Abstract: Métodos de inhibición de la replicación del virus de la gripe en una muestra biológica o un paciente, de reducción de la cantidad del virus de la gripe en una muestra biológica o un paciente y de tratamiento de gripe en un paciente, que comprende la administración a dicha muestra biológica o paciente de una cantidad efectiva de un compuesto representado por la fórmula estructural (1), o una de sus sales farmacéuticamente aceptables, en donde los valores de la fórmula estructural (1) son como se describen en la presente. Un compuesto está representado por la fórmula estructural (1) o una de sus sales farmacéuticamente aceptables, en donde los valores de la fórmula estructural (1) son como se describen en la presente. Una composición farmacéutica comprende una cantidad efectiva de tal compuesto o su sal farmacéuticamente aceptable y un portador, adyuvante o vehículo farmacéuticamente aceptable.
-
-
-
-
-
-
-
-
-